Repligen (NASDAQ:RGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research report sent to investors on Saturday.

Several other research analysts have also recently weighed in on the company. Barclays upped their price objective on Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Weiss Ratings downgraded Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, January 30th. Canaccord Genuity Group lifted their price objective on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Finally, Wells Fargo & Company raised their target price on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $177.92.

Repligen Stock Performance

Shares of RGEN opened at $143.58 on Friday. The firm has a market cap of $8.08 billion, a P/E ratio of 7,182.59, a PEG ratio of 2.59 and a beta of 1.13. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The firm’s 50 day moving average price is $161.45 and its two-hundred day moving average price is $145.40.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 20,000 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $154.61, for a total value of $3,092,200.00. Following the sale, the director directly owned 80,743 shares of the company’s stock, valued at approximately $12,483,675.23. This represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 49,657 shares of company stock worth $7,721,077 over the last quarter. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Repligen by 1.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after acquiring an additional 75 shares during the last quarter. NewEdge Wealth LLC lifted its holdings in Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its position in Repligen by 1.0% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 80 shares during the period. Drive Wealth Management LLC increased its holdings in shares of Repligen by 2.5% in the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 93 shares during the last quarter. Finally, Hilltop National Bank increased its holdings in shares of Repligen by 8.0% in the third quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.